EVALUATION OF HIGH DIMENTIONAL REDUCTION AND CLUSTERING IN THE PHENOTYPIC DICRIMINATION OF CD5+ B-CELL CHRONIC LYMPHOPROLIFERATIVE DISEASES.

BAEZ, NATALIA S; ARROYO DANIELA S; MANZONE-RODRIGUEZ CLARISA; WANG, JI M.; RODRIGUEZ, CECILIA M.; IRIBARREN PABLO

Congreso; REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIAS SAIC - SAI - SAFIS; 2020

B-cell chronic lymphoproliferative diseases (B-CLPD) are a biologically heterogeneous group of malignant diseases characterized by accumulation of mature B lymphocytes in the bone marrow (BM), peripheral blood (PB), and lymphoid tissues. Integration of a complex set of immunophenotypic, morphological, clinical, and cytogenetic information is essential for the subclassification of B-CLPD. Current clinical immunophenotyping generally include ≥8-color tubes, allowing precise characterization of normal, reactive and neoplastic leukocyte.The diagnostic approach developed by Euroflow Consortium was based on a lymphoid screening tube (LST), followed by 4 tubes of B-CLPD panel to classify and diagnose pathological samples according to the WHO classification. The use of the LST tube and B1 are mainly used for the discrimination of CD5+ B lymphoproliferative syndromes such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In recent years the volume and complexity of flow cytometry data has increased substantially. Consequently, new gating strategies and new approaches for cell population definition are required. The Euroflow protocol utilizes software incorporating a linear dimensionality-reduction transformation, principal component analysis (PCA). Since the biological samples do not present linear variations, it would be more useful to use non-linear algorithms that can better reproduce the data. As well as conducting an unsupervised analysis of the data that allows the identification of abnormal B-cell populations in routine clinical flow cytometric data